Please login to the form below

Not currently logged in
Email:
Password:

Afferent Pharma

This page shows the latest Afferent Pharma news and features for those working in and with pharma, biotech and healthcare.

Merck says Afferent’s chronic cough drug clears mid-stage trial

Merck says Afferent’s chronic cough drug clears mid-stage trial

MK-7264 reduces coughs per hour by 37%. Merck &Co's purchase of Afferent Pharma last year was all about a candidate drug for chronic cough - so it will be celebrating ... Merck (known as MSD outside North America) stumped up $500m upfront to buy Afferent

Latest news

  • Merck buys cough drug developer Afferent for $1.25bn Merck buys cough drug developer Afferent for $1.25bn

    Merck &Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate for chronic cough to its pipeline. ... Merck has been working on its own early-stage R&D programme in the P2X3 area, along with other big pharma

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics